Endothelins release tissue plasminogen activator and prostanoids.

[1]  C. Thiemermann,et al.  Endothelin‐1 inhibits platelet aggregation in vivo: a study with 111indium‐labelled platelets , 1990, British journal of pharmacology.

[2]  J. López-Belmonte,et al.  Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation , 1989, British journal of pharmacology.

[3]  J. Vane,et al.  Fibrinolytic activity of endothelin-3. , 1989, Thrombosis research.

[4]  P. Braquet,et al.  Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs , 1989, British journal of pharmacology.

[5]  C. Thiemermann,et al.  Endothelin-3: selectivity as an anti-aggregatory peptide in vivo. , 1989, European journal of pharmacology.

[6]  M. Rånby,et al.  Immunoreactivity of Tissue Plasminogen Activator and of Its Inhibitor Complexes , 1989, Thrombosis and Haemostasis.

[7]  J. Vane,et al.  Endothelin-1 contracts isolated vessels independently of dihydropyridine-sensitive Ca2+ channel activation. , 1989, European journal of pharmacology.

[8]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Thiemermann,et al.  Endothelin inhibits ex vivo platelet aggregation in the rabbit. , 1988, European journal of pharmacology.

[10]  P. Moore,et al.  Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. , 1988, European Journal of Pharmacology.

[11]  P. Moore,et al.  Prostanoids stimulate fibrinolysis in the rat. , 1988, Archives internationales de pharmacodynamie et de therapie.

[12]  J. Vane,et al.  Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[14]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[15]  M. Ishikawa,et al.  Endothelium‐dependent inhibition of platelet aggregation , 1986, British journal of pharmacology.

[16]  R. L. Schultz,et al.  Methods for the evaluation of human fibrinolysis; studies with two combined technics. , 1958, American journal of clinical pathology.

[17]  J. Vane,et al.  Endothelin‐1 and Endothelin‐3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit , 1989, Journal of Cardiovascular Pharmacology.

[18]  M. Redfield,et al.  Integrated cardiac, renal, and endocrine actions of endothelin. , 1989, The Journal of clinical investigation.

[19]  C. Thiemermann,et al.  Endothelin‐1 Releases Prostacyclin and Inhibits ex vivo Platelet Aggregation in the Anesthetized Rabbit , 1989, Journal of cardiovascular pharmacology.

[20]  J. Vane,et al.  Endothelin‐1 Releases Eicosanoids from Rabbit Isolated Perfused Kidney and Spleen , 1989, Journal of cardiovascular pharmacology.